Merck and Isomorphic Labs said they are entering into a research collaboration to discover small molecule candidates in oncology, according to STAT. No financial terms or specific targets were disclosed in the announcement.
This move signals another large pharma company seeking external innovation in cancer drug discovery. For pharma and biotech leaders, this may mean more competition for partnerships and a shift in how oncology pipelines are built. Further information on the collaboration’s scope will be important for assessing its impact.
The FDA has rejected a cell therapy for Duchenne muscular dystrophy developed by Capricor Therapeutics, according to STAT. The decision follows a lengthy review process, with the agency declining to approve the treatment for use in patients.
This outcome signals persistent regulatory hurdles for companies developing advanced therapies in rare diseases. For biotech and pharma executives, the decision adds to uncertainty in planning and investment for novel treatments. Firms may need to reassess risk and timelines for similar products.
STAT reports that Flagship is investing £100 million to establish 'AI-native platform companies' in the UK, targeting advances in human and planetary health. The initiative aims to create biotech firms that use artificial intelligence at their core.
This move signals growing interest in AI-driven approaches within the biotech sector. For pharma and biotech executives, it may mean increased competition and new opportunities for collaboration or investment as AI becomes more central to research and development.
Major technology companies including SpaceX, Nvidia, Amazon, and Stripe have led a surge in AI startup acquisitions, with billion-dollar deals hitting their highest level since 2021, according to Business Insider. Notable transactions include SpaceX’s $60 billion purchase of Cursor, Nvidia’s $12.9 billion agreement to buy Hugging Face, Stripe’s $8 billion acquisition of OpenRouter, and AMD’s $8.2 billion deal for World Labs. Amazon is reportedly in talks for a $7 billion acquisition of Decart, while Nvidia is considering Reflection AI at a $25 billion valuation.
The trend is driven by a rush to secure AI talent and technology. Some deals are described as large-scale acqui-hires, with acquirers seeking skilled teams and advanced AI systems. The presence of trillion-dollar tech companies has made multibillion-dollar purchases more common. Strategic buyers can sometimes benefit from share price increases following deal announcements, partially offsetting acquisition costs.
For leaders in regulated sectors, this wave of AI M&A raises questions about access to talent, competitive positioning, and the cost of missing out on key technology. The market’s appetite for venture-backed acquisitions is changing expectations for liquidity and exit strategies, especially as valuations for AI firms continue to climb.
According to STAT, Novartis presented data at the AHA conference showing its drug reduced a key risk marker for cardiovascular disease but did not decrease the actual risk of heart attack or stroke. The result raises new questions about the link between biomarkers and clinical outcomes.
This matters for pharma and biotech executives as it challenges the value of targeting certain biomarkers in drug development. Companies may need to reassess their clinical trial endpoints and consider broader measures of patient benefit.
Ballistic Ventures, a venture capital firm focused on cybersecurity, has filed to raise $490 million across two new funds, according to regulatory documents seen by TechCrunch. The firm aims to secure $360 million for its third flagship fund and $130 million for a separate vehicle, Ballistic Ventures Fund B. No sales had been recorded at the time of filing.
The fundraising effort follows a surge in AI-enabled cyberattacks and a corresponding rise in venture capital interest in the sector. According to a JPMorgan Chase report, U.S. cybersecurity startups raised $11.5 billion in 2025, with AI-enabled companies making up about 72% of deals through May. Ballistic Ventures, founded in 2021, has previously backed firms acquired by major players like Palo Alto Networks and CrowdStrike.
Ballistic's leadership includes former Kleiner Perkins partner Ted Schlein and experienced cybersecurity executives. Its strategy is seen as similar to other specialist investors, but its connections to established venture firms may offer an edge. The firm declined to comment on the fundraising plans.
Microsoft has also warned that AI is accelerating the pace and scale of cyberattacks. Senior executives in regulated sectors should monitor how AI is changing the risk environment and influencing where capital flows in cybersecurity.
STAT reports that Servier has announced a surprise setback for a drug in development for a form of muscular dystrophy with no current treatment. The drug, valued at $1.55 billion, failed its first major clinical test according to the company.
This development matters to pharma and biotech executives because it highlights the risk and uncertainty in rare disease drug pipelines. Companies with similar assets may face renewed scrutiny from investors and regulators. The news could prompt a review of clinical trial strategies and portfolio priorities across the sector.
Eli Lilly said its investigational drug retatrutide was more effective at lowering blood sugar and reducing weight than Novo Nordisk’s Ozempic in a large diabetes study, according to STAT. The announcement positions Lilly as a strong competitor in the diabetes treatment market.
For pharma executives, this signals a shift in the competitive field for diabetes therapies. The result could influence future regulatory reviews, payer decisions and market share in a major therapeutic area.
STAT reports that Artiva is shutting down its autoimmune cell therapy trial after two patients died. The news comes as drugmakers have shown interest in using cancer therapy strategies for autoimmune conditions, but these recent deaths have raised new concerns about safety and risk.
For senior executives in biotech and pharma, this development signals increased scrutiny on adapting cancer treatments for other diseases. Companies may need to reassess trial protocols and risk management processes. The outcome may affect investor confidence and regulatory expectations in the sector.
Imagine an artificial intelligence system that has been reliable for months, consistently offering accurate recommendations. But then, it makes a mistake or cannot continue without human help. The employee overseeing the AI must intervene but may lack the expertise needed. This scenario highlights a growing latent risk: employees, while still responsible, may lose the skills necessary to step in effectively as AI takes over more tasks. The better AI performs, the more work shifts to monitoring rather than doing, making human intervention rarer and more challenging. This shift creates a paradox where employees must make harder judgments less often, risking preparedness and capability deterioration. Organizations must rethink accountability, recognizing that authority, responsibility, and actual capability can diverge when AI is involved. Current measures focusing on AI accuracy or override frequency often miss this subtle shift. Continuous governance and deliberate training are essential to maintain the human skills needed as a safety net when AI hits its limits. Ultimately, organizations must decide which human abilities remain critical and ensure they're ready when called upon.